Impact Factor 4.137 | CiteScore 4.28
More on impact ›

Review ARTICLE Provisionally accepted The full-text will be published soon. Notify me

Front. Oncol. | doi: 10.3389/fonc.2019.01293

Epigenetic regulation of miRNA expression in malignant mesothelioma: miRNAs as biomarkers of early diagnosis and therapy

  • 1Marche Polytechnic University, Italy
  • 2Department of Clinical and Molecular Sciences, Faculty of Medicine and Surgery, Marche Polytechnic University, Italy
  • 3School of Medicine, Griffith Health, Griffith University, Australia

Asbestos exposure leads to epigenetic and epigenomic modifications that in association with ROS-induced DNA damage contribute to cancer onset. Few miRNAs epigenetic regulated in MM have been described in literature, and miR-126 is one of them which expression is regulated by epigenetic mechanisms. Asbestos-exposure induces early changes of the miRNAs, which are reversibly expressed as protective species, and their irreversibly reflects the inability of the cells to restore the physiological miRNA levels despite the cessation of carcinogen exposure. Changes in miRNA expression, which results from genetic/epigenetic changes during tumour formation and evolution, can be detected in fluids and used as cancer biomarkers. This article reviews the epigenetic mechanisms involved in miRNA expression in MM, focusing on their role as biomarkers of early diagnosis and therapeutic effects.

Keywords: Malignant mesothelioma, Epi-miRNAs, miR-126, Epigenetic biomarkers, early diagnosis

Received: 01 Jul 2019; Accepted: 07 Nov 2019.

Copyright: © 2019 Tomasetti, Gaetani, Monaco, Neuzil and Santarelli. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence:
Dr. Marco Tomasetti, Marche Polytechnic University, Ancona, Italy,
Prof. Lory Santarelli, Department of Clinical and Molecular Sciences, Faculty of Medicine and Surgery, Marche Polytechnic University, Ancona, 60020, Italy,